Rockefeller Capital Management L.P. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Rockefeller Capital Management L.P. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 81.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 137,838 shares of the company's stock after purchasing an additional 61,800 shares during the period. Rockefeller Capital Management L.P. owned 0.14% of Intellia Therapeutics worth $1,607,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. increased its stake in Intellia Therapeutics by 125.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock worth $1,411,000 after acquiring an additional 67,276 shares during the last quarter. Avanza Fonder AB purchased a new position in shares of Intellia Therapeutics during the fourth quarter worth about $421,000. Barclays PLC increased its position in shares of Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after purchasing an additional 44,022 shares during the last quarter. Geode Capital Management LLC raised its stake in Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company's stock valued at $48,164,000 after purchasing an additional 49,367 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on NTLA. Citigroup raised their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. BMO Capital Markets cut their target price on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Wedbush reaffirmed a "neutral" rating and set a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $36.68.

Intellia Therapeutics Trading Down 2.5 %

NASDAQ NTLA traded down $0.21 on Wednesday, hitting $8.11. The company's stock had a trading volume of 2,562,048 shares, compared to its average volume of 2,369,773. The firm has a market cap of $839.01 million, a P/E ratio of -1.49 and a beta of 2.23. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.18. The company's 50-day simple moving average is $8.83 and its 200 day simple moving average is $12.01.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.